Manchester, 27 April 2021 – SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on the microbiome, announces that it has initiated a research and development programme in oral health with the University of Manchester (“the University”), as discussed when the Company executed its Placing in October 2020.
SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announces that it has initiated a research programme with the University of Manchester (“the University”) to investigate and develop microbiome formulations that support natural anti-inflammatory response to a range of environmental challenges. Expanding the collaboration with the University was one of the areas of investment laid out by the Company when it raised funds via placing and open offer in October 2020.
(“SkinBioTherapeutics” or “the Company”)
Expanded enrolment for AxisBiotix-PsTM food supplement consumer study
- Study size increased to 250 from 200, following high demand for places
- Study to commence by end February 2021
- Participants’ feedback on AxisBiotix-PsTM to be monitored through smart devices
SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announces that AxisBiotix Limited, a wholly owned subsidiary of the Company, has increased the size of its food supplement consumer study from 200 to 250 participants, following a high level of demand.
AxisBiotix Limited commences enrolment for its food supplement consumer study. To see more and how you can participate then please go to axisbiotix.com and also watch our video.
For more details, please follow the link below:
SkinBioTherapeutics plc (AIM: SBTX or the “Company”) a life sciences company focused on skin health, is pleased to announce it has conditionally raised £4.0 million by way of a Placing to new and existing institutional investors.
Furthermore, to enable other Shareholders who are not able to participate in the Placing an opportunity to subscribe for new Ordinary Shares, the Company is proposing to raise up to an additional c.£0.5 million by way of an Open Offer made to Qualifying Shareholders.